NASDAQ$LFST
LifeStance Health Group Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
LifeStance's Q1 2023 results reflected a mix of revenue growth and strategic investments.
LifeStance Health Group reported a 24% increase in total revenue to $252.6 million for Q1 2023. The company's net loss was $34.2 million, an improvement compared to the prior year's $62.3 million. The company is raising full year revenue and Center Margin guidance while reaffirming full year Adjusted EBITDA guidance.
- Total revenue increased by 24% to $252.6 million.
- Total clinicians reached 5,961, up 19% year-over-year.
- Net loss was $34.2 million, primarily driven by stock-based compensation.
- Adjusted EBITDA was $10.1 million.
Headline financials
Revenue & EPS history
LifeStance · Revenue · Quarterly
$253M
Forward guidance
LifeStance is raising full year revenue and Center Margin guidance, with the following outlook for 2023:
Tailwinds
- The Company expects full year revenue of $990 million to $1.02 billion
- Center Margin of $274 to $290 million
- Adjusted EBITDA of $50 to $62 million
- For the second quarter of 2023, the Company expects total revenue of $250 to $260 million
- Center Margin of $69 to $76 million
Headwinds
- The Company expects Adjusted EBITDA of $10 to $16 million for the second quarter of 2023
- We may not grow at the rates we historically have achieved or at all, even if our key metrics may imply future growth, including if we are unable to successfully execute on our growth initiatives and business strategies
- If we fail to manage our growth effectively, our expenses could increase more than expected, our revenue may not increase proportionally or at all, and we may be unable to execute on our business strategy
- Our ability to recruit new clinicians and retain existing clinicians
- If reimbursement rates paid by third-party payors are reduced or if third-party payors otherwise restrain our ability to obtain or deliver care to patients, our business could be harmed
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2023
-4.5%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+1.2%
Avg return
30 days after
42%
8 / 19 earnings
Positive
+24.6%
Q4 2023
Best reaction
-49.7%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +19.8% | +7.7% | +0.5% | |
| Q4 2025 | +4.3% | +0.0% | -11.5% | |
| Q3 2025 | -3.6% | +29.1% | +30.1% | |
| Q1 2025 | -16.0% | -10.7% | -10.8% | |
| Q4 2024 | +3.1% | +6.8% | -10.8% | |
| Q3 2024 | +3.2% | +3.8% | +2.9% | |
| Q2 2024 | +1.6% | +6.0% | +26.1% | |
| Q1 2024 | -1.7% | +5.9% | -19.1% | |
| Q4 2023 | +24.6% | +21.8% | -3.4% | |
| Q3 2023 | -9.4% | -8.9% | +7.9% | |
| Q2 2023 | -5.0% | -7.4% | -17.1% | |
| Q1 2023 | -1.4% | +1.1% | +1.7% | |
| Q4 2022 | +22.2% | +23.8% | +65.6% | |
| Q3 2022 | -30.4% | -15.9% | -23.0% | |
| Q2 2022 | +6.2% | +10.8% | +29.3% | |
| Q1 2022 | -13.9% | +0.4% | +10.1% | |
| Q4 2021 | -12.7% | -5.9% | +4.2% | |
| Q3 2021 | -27.3% | -22.8% | -29.1% | |
| Q2 2021 | -49.7% | -40.6% | -30.2% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro